Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right
heart function, exercise capacity, quality of life and survival. Current therapies have …

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Background Current therapies for pulmonary arterial hypertension have been adopted on
the basis of short-term trials with exercise capacity as the primary end point. We assessed …

Background: Right ventricular (RV) adaptation to acute and chronic pulmonary hypertensive
syndromes is a significant determinant of short-and long-term outcomes. Although …

Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2
trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …

Pulmonary arterial hypertension is a progressive disorder in which endothelial dysfunction
and vascular remodeling obstruct small pulmonary arteries, resulting in increased …

Background Several randomised controlled studies and a previous meta-analysis have
reported conflicting results regarding the effect of combined targeted therapy compared with …

Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …

Background Treprostinil, a prostacyclin analogue, is effective for the treatment of pulmonary
arterial hypertension. However, information is scarce regarding treprostinil for treatment of …